Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
A Phase I/II Study of Sorafenib With Combination of Thalidomide in Advanced or Metastatic Hepatocellular Carcinoma
Sponsor: Chang Gung Memorial Hospital
Terminated
Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early this trial.
Other terminated trials from Chang Gung Memorial Hospital
Other Hepatocellular Carcinoma trials with similar outcome
Listed as NCT00971126, this PHASE1/PHASE2 trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Chang Gung Memorial Hospital, it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chang Gung Memorial Hospital
- National Cheng-Kung University Hospital
- National Health Research Institutes, Taiwan
For direct contact, visit the study record on ClinicalTrials.gov .